Profile data is unavailable for this security.
About the company
Amplifon SpA is an Italy-based company active in the hearing care retail market. The Company provides personalized solutions and customer care to hearing-impaired people. It offers a wide range of services from diagnosing hearing difficulties, to fitting, servicing and maintaining hearing aids. The Company is organized in three geographical operating segments: Europe, Middle East and Africa - EMEA - (Italy, France, The Netherlands, Germany, the United Kingdom, Ireland, Spain, Portugal, Switzerland, Belgium, Luxemburg, Hungary, Egypt, Turkey, Poland and Israel), Americas (USA, Canada, Chile, Argentina, Ecuador, Colombia, Panama and Mexico) and Asia-Pacific (Australia, New Zealand, India and China).
- Revenue in EUR (TTM)2.36bn
- Net income in EUR155.88m
- Incorporated--
- Employees14.38k
- LocationAmplifon SpAVia Ripamonti 133MILANO 20141ItalyITA
- Phone+39 2574721
- Fax+39 257300033
- Websitehttps://www.amplifon.com/
More ▼
Mergers & acquisitions
| Acquired company | AMP:MIL since announced | Transaction value |
|---|---|---|
| Miracle-Ear Centers of Arkansas LLC | -20.60% | -- |
| Las Davis Enterprises Inc | -20.60% | -- |
| Hearing Pro Inc | -20.60% | -- |
| Audical SRL | -20.95% | -- |
| Living Sounds Hearing Centre | -17.56% | -- |
Data delayed at least 15 minutes, as of Nov 25 2024 15:49 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambu A/S | 722.95m | 31.51m | 3.59bn | 5.20k | 128.91 | 5.43 | 28.76 | 4.97 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 2.92bn | 147.06m | 3.71bn | 11.85k | 27.06 | 1.51 | 11.61 | 1.27 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 948.56m | 150.41m | 4.01bn | 4.65k | 26.58 | 5.22 | 18.94 | 4.23 | 1.00 | 1.00 | 6.31 | 5.10 | 0.7434 | 4.34 | 4.07 | 204,166.20 | 11.82 | -- | 16.42 | -- | 34.18 | -- | 15.90 | -- | 1.06 | -- | 0.1086 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| Sectra AB | 157.42m | 38.89m | 4.32bn | 1.22k | 118.74 | 32.09 | 90.87 | 27.46 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Carl Zeiss Meditec AG | 2.07bn | 203.20m | 4.96bn | 4.95k | 24.34 | -- | -- | 2.40 | 2.28 | 2.28 | 23.14 | -- | -- | -- | -- | 428,397.90 | -- | 9.56 | -- | 11.72 | 55.12 | 57.84 | 9.84 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| Ypsomed Holding AG | 662.66m | 79.88m | 5.23bn | 2.60k | 65.52 | 7.84 | 32.29 | 7.90 | 5.45 | 5.45 | 45.20 | 45.56 | 0.5828 | 5.28 | 5.46 | 268,759.60 | 7.03 | 4.41 | 11.60 | 6.81 | 35.44 | 27.26 | 12.06 | 7.38 | 0.5060 | 13.12 | 0.3434 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Amplifon SpA | 2.36bn | 155.88m | 5.26bn | 14.38k | 33.69 | 4.69 | 11.69 | 2.23 | 0.6898 | 0.6898 | 10.40 | 4.96 | 0.6255 | 20.32 | 10.83 | 164,118.00 | 4.13 | 4.31 | 6.24 | 5.81 | 23.55 | 59.01 | 6.61 | 7.28 | 0.4043 | 5.23 | 0.6064 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| ConvaTec Group PLC | 2.11bn | 147.07m | 5.84bn | 10.13k | 39.82 | 3.68 | 16.37 | 2.76 | 0.0595 | 0.0595 | 0.8542 | 0.6443 | 0.5965 | 2.47 | 5.89 | 173,352.10 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| DiaSorin SpA | -100.00bn | -100.00bn | 6.01bn | 3.19k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.30 | -- | 11.50 | -- | 66.70 | -- | 21.25 | -- | -- | -- | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
Data as of Nov 25 2024. Currency figures normalised to Amplifon SpA's reporting currency: Euro EUR
12.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Comgest SAas of 30 Aug 2024 | 5.23m | 2.31% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 4.48m | 1.98% |
| Allianz Global Investors GmbHas of 30 Sep 2024 | 2.79m | 1.23% |
| Cr�dit Mutuel Asset Management SAas of 28 Mar 2024 | 2.42m | 1.07% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 2.37m | 1.05% |
| Amundi Asset Management SA (Investment Management)as of 20 Nov 2024 | 2.33m | 1.03% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.29m | 1.01% |
| Norges Bank Investment Managementas of 02 May 2024 | 2.06m | 0.91% |
| DNCA Finance SAas of 31 Dec 2023 | 1.67m | 0.74% |
| Mirova SA (Investment Management)as of 30 Aug 2024 | 1.56m | 0.69% |
More ▼
Data from 30 Jun 2024 - 20 Nov 2024Source: FactSet Research Systems Inc.
